Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.LifeCycle Pharma has initiated a Phase II clinical trial of LCP-Tacro for the treatment of autoimmune hepatitis, a disease which causes a person's body to reject its own liver.
Subscribe to our email newsletter
The Phase II clinical trial is a open-label, multi-center, prospective, randomized study to evaluate the efficacy, safety and tolerability of LCP-Tacro tablets given once daily versus azathioprine (AZA), each in combination with prednisone, for the treatment of autoimmune hepatitis. Up to 60 patients will be randomized (1:1) to receive treatment with LCP-Tacro + prednisone versus AZA + prednisone.
The clinical trial is expected to enroll up to 60 patients in up to 12 centers throughout the US and Canada. The company expects to report top-line clinical trial results in the first half of 2009.